Gene · 23400
Papers1,821
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,821
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Retraction Notice to: Lysosomal polyamine storage upon ATP13A2 loss impairs β-glucocerebrosidase via altered lysosomal pH and electrostatic hydrolase-lipid interactions. | Cell Rep | 2026 | 42804365 | PubTator, text mining | PubMed |
| Genetic architecture and molecular pathogenesis of Parkinson's disease: emerging mechanisms and therapeutic targets. | Metab Brain Dis | 2026 | 42803978 | PubTator, text mining | PubMed |
| Dysregulated polyamine metabolism in neurological disorders: molecular mechanisms and therapeutic opportunities. | Mol Biol Rep | 2026 | 42771220 | PubTator, text mining | PubMed |
| Defective ATP13A2-ITCH-ALIX signaling impairs intraluminal vesicle biogenesis and increases neuronal vulnerability. | Cell Signal | 2026 | 42762936 | PubTator, text mining | PubMed |
| Exploring cerebral small vessel disease signatures in familial Parkinson's disease. | Sci Rep | 2026 | 42706363 | PubTator, text mining | PubMed |
| Polyamine Metabolism in Brain Health and Disease. | Neuropharmacol Ther | 2026 | 42631064 | PubTator, text mining | PubMed |
| Polyamines buffer labile iron to suppress ferroptosis. | Cell | 2026 | 42600612 | PubTator, text mining | PubMed |
| ATP13A2 Promotes Endothelial Angiogenic Phenotypes and Is Associated With Poor Prognosis in Liver Hepatocellular Carcinoma. | Mol Carcinog | 2026 | 42574576 | PubTator, text mining | PubMed |
| Parkinson's disease genetics across diverse ancestries: an observational genetic study of causal and risk variants with translational implications. | Lancet Neurol | 2026 | 42456684 | PubTator, text mining | PubMed |
| Correction to "Structural Dynamics and Catalytic Mechanism of ATP13A2 (PARK9) from Simulations". | J Phys Chem B | 2026 | 42439853 | PubTator, text mining | PubMed |
| A PARK9 iPSC-Derived Dopaminergic Neuron Model Enables Drug Screening Targeting Autophagy-Lysosome Pathway Dysfunction in Parkinson's Disease. | J Neurochem | 2026 | 42400323 | PubTator, text mining | PubMed |
| iSCORE-PD: an isogenic stem cell collection to research Parkinson's disease. | Nat Commun | 2026 | 42310027 | PubTator, text mining | PubMed |
| Genetic Variants and Clinical Characteristics of Young-Onset Parkinson's Disease in the Hakka Population of Western Fujian. | Brain Behav | 2026 | 42204920 | PubTator, text mining | PubMed |
| ATP13A2 promoted cell stemness, cisplatin resistance, autophagy, and cell progression of bladder cancer. | Front Immunol | 2026 | 42183293 | PubTator, text mining | PubMed |
| Role of Lysosomal Genes for Parkinson's Pathogenesis: Insights from Molecular Mechanism to Therapeutic Strategies. | Curr Rev Clin Exp Pharmacol | 2026 | 42152630 | PubTator, text mining | PubMed |
| PPARα and RXRα in the regulation of neuronal ceroid lipofuscinosis genes: implications for Batten disease therapy. | NeuroImmune Pharm Ther | 2026 | 42146023 | PubTator, text mining | PubMed |
| Multi-omics analysis of the mechanism by ATP13A2 regulates the tumor microenvironment and prognosis in hepatocellular carcinoma. | Cancer Cell Int | 2026 | 42104358 | PubTator, text mining | PubMed |
| ATP13A2 Loss of Function-Driven Polyamine Dysregulation Induces SAM Depletion and Epigenetic Astrocyte Toxicity. | bioRxiv | 2026 | 41993310 | PubTator, text mining | PubMed |
| Genetic Landscape of Monogenic Parkinson's Disease in the African Population-A Systematic Review. | Mov Disord | 2026 | 41958045 | PubTator, text mining | PubMed |
| Clinical Evaluation of Three KRS Families and Cellular Analysis of Distinct ATP13A2 Mutations Reveal Different Levels of Iron Accumulation. | J Neurochem | 2026 | 41944191 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23400/papers